The U.S. Food and Drug Administration issued a recall of surgical staplers made by Johnson & Johnson’s Ethicon unit, warning that the use of the devices could cause serious injury or death.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.
Johnson & Johnson agreed to pay about $1 billion to resolve the bulk of lawsuits claiming the company sold defective metal-on-metal hip implants that ultimately had to be removed, Bloomberg reported, citing people with knowledge of the matter.
GlaxoSmithKline Plc said the company’s three-in-one drug Trelegy Ellipta met the main goal of a late-stage asthma study, signaling a possible boost to the British drugmaker’s lung medicines division.
A recent report written by SVB Leerink analysts that looked at eight companies and their research-and-development portfolios found that in the past five years, they progressed only 24 percent of their new molecular entities to approval.
Abbott, the U.S. Department of Defense and TRACK-TBI Partner to Study Point-of-Care Blood Test for Concussions
Abbott announced the next phase of partnership with the U.S. Department of Defense and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury efforts of its kind.
In a first, heart surgeons in Poland used 3D goggles to help them see inside a patient’s chest as they opened up a narrowed heart valve, according to a report in the European Heart Journal.
March 2019 was a busy month for biopharma and medical device company initial public offerings.
Integra Lifesciences Holdings Corp. received a warning letter from the U.S. Food and Drug Administration regarding the medical device maker ‘s manufacturing facility in Boston.